Immuneering (IMRX) Cash from Financing Activities (2020 - 2026)

Immuneering's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $180760.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 98.69% year-over-year to $180760.0; the TTM figure through Mar 2026 stood at $213.0 million (up 1074.32% YoY), while the FY2025 annual figure was $226.6 million, up 4172.32% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $180760.0, up from -$357523.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $213.2 million in Q3 2025, with the low at -$357523.0 in Q4 2025.
• The 5-year median for Cash from Financing Activities is $104272.0 (2022), against an average of $16.3 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities tumbled 2556.14% in 2022, then jumped 101297.86% in 2023.
• Immuneering's Cash from Financing Activities stood at -$184677.0 in 2022, then soared by 104.24% to $7835.0 in 2023, then plunged by 623.14% to -$40988.0 in 2024, then tumbled by 772.26% to -$357523.0 in 2025, then soared by 150.56% to $180760.0 in 2026.
• Business Quant data shows IMRX's Cash from Financing Activities at $180760.0 in Q1 2026, -$357523.0 in Q4 2025, and $213.2 million in Q3 2025.